Pharma Capital

Medtronic recalls diabetes infusion sets on concerns of over-delivery of insulin risk

"Our Medtronic Diabetes team will work as quickly as possible to complete all exchanges to the new and enhanced set and fully support our customers throughout this process," said Francine Kaufman
Medtronic
Medtronic is the world’s largest manufacturer of pacemakers and defibrillators

Medtronic Inc (NYSE:MDT) has issued a voluntary recall of its diabetes infusion sets that are used with all models of its insulin pumps.

The recall comes after reports from patients that a discontinued component, the vent membrane, may be susceptible to being blocked by fluid during priming and fill-tubing.

The company said this can lead to over-delivery of insulin shortly after an infusion set change, which can lead to hypoglycemia.

READ: Medtronic skips lower as IT disruption hampers first quarter sales

Medtronic has recommended that customers use only infusion sets made with the new and enhanced membrane.

"Our Medtronic Diabetes team will work as quickly as possible to complete all exchanges to the new and enhanced set and fully support our customers throughout this process," said Francine Kaufman, chief medical officer of Medtronic's diabetes group.



Register here to be notified of future MDT Company articles
View full MDT profile

Medtronic Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.